Alan Kooi Davis (Alan K Davis)

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 24

Top Topics

Major Depressive Disorder

Cognitive Impairment

Top Venues

Journal of psychoactive drugs

Journal of psychopharmacology (Oxford, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Adam W Levin, Rafaelle Lancelotta, Nathan D Sepeda, Natalie Gukasyan, Sandeep Nayak, Theodore L Wagener, Frederick S Barrett, Roland R Griffiths, Alan Kooi Davis
The therapeutic alliance between study participants and intervention facilitators is associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for major depressive disorder. PloS one 19 (3) (2024)
Adam W Levin, Rafaelle Lancelotta, Nathan D Sepeda, Natalie Gukasyan, Sandeep Nayak, Theodore L Wagener, Frederick S Barrett, Roland R Griffiths, Alan Kooi Davis
The therapeutic alliance between study participants and intervention facilitators is associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for major depressive disorder. PloS one 19 (3) (2024)
Adam W Levin, Rafaelle Lancelotta, Nathan D Sepeda, Natalie Gukasyan, Sandeep Nayak, Theodore L Wagener, Frederick S Barrett, Roland R Griffiths, Alan Kooi Davis
The therapeutic alliance between study participants and intervention facilitators is associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for major depressive disorder. PloS one 19 (3) (2024)
Alan Kooi Davis, Adam W Levin, Paul B Nagib, Stacey B Armstrong, Rafaelle L Lancelotta
Study protocol of an open-label proof-of-concept trial examining the safety and clinical efficacy of psilocybin-assisted therapy for veterans with PTSD. BMJ open 13 (5) (2023)
Alan Kooi Davis, Yitong Xin, Nathan Sepeda, Lynnette A Averill
Open-label study of consecutive ibogaine and 5-MeO-DMT assisted-therapy for trauma-exposed male Special Operations Forces Veterans: prospective data from a clinical program in Mexico. The American journal of drug and alcohol abuse (2023)
Alan Kooi Davis, Adam W Levin, Paul B Nagib, Stacey B Armstrong, Rafaelle L Lancelotta
Study protocol of an open-label proof-of-concept trial examining the safety and clinical efficacy of psilocybin-assisted therapy for veterans with PTSD. BMJ open 13 (5) (2023)
Alan Kooi Davis, Adam W Levin, Paul B Nagib, Stacey B Armstrong, Rafaelle L Lancelotta
Study protocol of an open-label proof-of-concept trial examining the safety and clinical efficacy of psilocybin-assisted therapy for veterans with PTSD. BMJ open 13 (5) (2023)
Alan Kooi Davis, Adam W Levin, Paul B Nagib, Stacey B Armstrong, Rafaelle L Lancelotta
Study protocol of an open-label proof-of-concept trial examining the safety and clinical efficacy of psilocybin-assisted therapy for veterans with PTSD. BMJ open 13 (5) (2023)
Nicolas G Glynos, Jennifer Pierce, Alan Kooi Davis, Jenna McAfee, Kevin F Boehnke
Knowledge, Perceptions, and Use of Psychedelics among Individuals with Fibromyalgia. Journal of psychoactive drugs (2022)
Terence H W Ching, Alan Kooi Davis, Yitong Xin, Monnica T Williams
Effects of Psychedelic Use on Racial Trauma Symptoms and Ethnic Identity among Asians in North America. Journal of psychoactive drugs (2022)
Natalie Gukasyan, Alan Kooi Davis, Frederick S Barrett, Mary P Cosimano, Nathan D Sepeda, Matthew W Johnson, Roland R Griffiths
Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. Journal of psychopharmacology (Oxford, England) 36 (2) (2022)
Meredith L Philyaw-Kotov, Maureen A Walton, Brianne Brenneman, Miriam Gleckman-Krut, Alan Kooi Davis, Erin Elizabeth Bonar
What undergraduates want in campus sexual assault prevention programming: Findings from a formative research study. Journal of American college health : J of ACH (2021)
Malin Vedøy Uthaug, Alan Kooi Davis, Trevor Forrest Haas, Dawn Davis, Sean B Dolan, Rafael Lancelotta, Christopher Timmermann, Johannes G Ramaekers
The epidemiology of mescaline use: Pattern of use, motivations for consumption, and perceived consequences, benefits, and acute and enduring subjective effects. Journal of psychopharmacology (Oxford, England) (2021)
Alan Kooi Davis, Yitong Xin, Nathan D Sepeda, Albert Garcia-Romeu, Monnica T Williams
Increases in Psychological Flexibility Mediate Relationship Between Acute Psychedelic Effects and Decreases in Racial Trauma Symptoms Among People of Color. Chronic stress (Thousand Oaks, Calif.) 5 (2021)
Alan Kooi Davis, Frederick S Barrett, Sara So, Natalie Gukasyan, Thomas C Swift, Roland R Griffiths
Development of the Psychological Insight Questionnaire among a sample of people who have consumed psilocybin or LSD. Journal of psychopharmacology (Oxford, England) 35 (4) (2021)
Alan Kooi Davis, Gabrielle Agin-Liebes, Megan España, Brian Pilecki, Jason Luoma
Attitudes and Beliefs about the Therapeutic Use of Psychedelic Drugs among Psychologists in the United States. Journal of psychoactive drugs (2021)
Rafael L Lancelotta, Alan Kooi Davis
Use of Benefit Enhancement Strategies among 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) Users: Associations with Mystical, Challenging, and Enduring Effects. Journal of psychoactive drugs 52 (3) (2020)
Jason B Luoma, Christina Chwyl, Geoff J Bathje, Alan Kooi Davis, Rafael Lancelotta
A Meta-Analysis of Placebo-Controlled Trials of Psychedelic-Assisted Therapy. Journal of psychoactive drugs 52 (4) (2020)
Alan Kooi Davis, John M Clifton, Eric G Weaver, Ethan S Hurwitz, Matthew W Johnson, Roland R Griffiths
Survey of entity encounter experiences occasioned by inhaled N,N-dimethyltryptamine: Phenomenology, interpretation, and enduring effects. Journal of psychopharmacology (Oxford, England) 34 (9) (2020)
Alan Kooi Davis, Lynnette A Averill, Nathan D Sepeda, Joseph P Barsuglia, Timothy Amoroso
Psychedelic Treatment for Trauma-Related Psychological and Cognitive Impairment Among US Special Operations Forces Veterans. Chronic stress (Thousand Oaks, Calif.) 4 (2020)
Alan Kooi Davis, Brooke J Arterberry
Passion for Marijuana Use Mediates the Relations between Refusal Self-Efficacy and Marijuana Use and Associated Consequences. Journal of psychoactive drugs 51 (4) (2019)
Roland R Griffiths, Ethan S Hurwitz, Alan Kooi Davis, Matthew W Johnson, Robert Jesse
Survey of subjective "God encounter experiences": Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT. PloS one 14 (4) (2019)
Alan Kooi Davis, Sara So, Rafael Lancelotta, Joseph P Barsuglia, Roland R Griffiths
5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety. The American journal of drug and alcohol abuse 45 (2) (2019)
Alan Kooi Davis, Elise Renn, Austin-Marley Windham-Herman, Martin Polanco, Joseph P Barsuglia
A Mixed-Method Analysis of Persisting Effects Associated with Positive Outcomes Following Ibogaine Detoxification. Journal of psychoactive drugs 50 (4) (2018)